期刊文献+

EB病毒基因Z2A原核表达载体的构建与表达 被引量:5

Construction and expression of prokaryotic expression vector containing EB virus gene Z2A
原文传递
导出
摘要 目的构建EB病毒基因LMP2A、BZLF1重组分泌性表达质粒Ag85B,然后将它成功转化成卡介苗。方法分别用PCR扩增Ag85B信号序列和LMP2A和BZLF1融合基因,将Ag85B信号序列与大肠杆菌-卡介苗穿梭质粒pMV261重组构建获得质粒pMVS。然后将LMP2A和BZLF1融合基因Z2A与质粒pMVS重组获得质粒pMVZ2A,将其电转化卡介苗,用SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)对其结果进行分析。结果信号序列与LMP2A和BZLF1融合基因被正确插入分泌表达载体pMV261。重组质粒经限制性内切酶双酶切、PCR扩增、基因测序等鉴定。蛋白纯化后可得到一条带。结论 pMVZ2A在BCG中能够分泌表达,本研究为获得抗结核杆菌和EB病毒的双价疫苗奠定了基础。 Objective To construct a recombinant secretory plasmid of Bacillus Calmette-Guerin(BCG) Ag85B-fused EB virus LMP2A and BZLF1 genes,and then transform it into BCG.Methods BCG-Ag85B signal sequence and Z2A gene were amplified from the genome of BCG and Z2A by PCR,respectively.BCG-Ag85B signal sequence was cloned into E.coli-BCG shuttle-vector pMV261 to obtain pMVS.The new recombinant plasmid of pMVZ2A was constructed by inserting the Z2A gene into pMVS and transformed into BCG by electrotransformation.The recombinant proteins were analyzed by SDS-PAGE.Results The cloned genes of BCG-Ag85B and Z2A were correctly inserted into the vector pMV261.The recombinant plasmid of pMVZ2A was identified by double restriction enzyme digestion,PCR amplification and gene sequencing.Conclusions pMVZ2A effectively expressed Z2A protein in BCG.The study provided a basis for BCG reconstruction and the development of new bivalent vaccine agaisnt EB virus and mycobacterium tuberculosis.
出处 《中国病毒病杂志》 CAS 2011年第4期282-286,共5页 Chinese Journal of Viral Diseases
基金 山东省卫生厅基金(2007HW035) 济宁医学院青年基金项目资助
关键词 人类疱疹病毒4型 卡介苗 基因融合 基因载体 Z2A Human herpesvirus type 4 BCG Gene fusion Genetic vectors Z2A
  • 相关文献

参考文献23

  • 1孙华,姚堃,陈云,周锋.Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells[J].Chinese Medical Journal,2004(10):1558-1563. 被引量:3
  • 2Henry M. Rosevear,Andrew J. Lightfoot,Michael A. O’Donnell,Thomas S. Griffith.The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette–Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder[J]. Cancer and Metastasis Reviews . 2009 (3-4) 被引量:1
  • 3Wujiang Liu,Michael A. O’Donnell,Xiaohong Chen,Ruifa Han,Yi Luo.Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro[J]. Cancer Immunology, Immunotherapy . 2009 (10) 被引量:1
  • 4LaMont J. Barlow,James M. McKiernan,Mitchell C. Benson.The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience[J]. World Journal of Urology . 2009 (3) 被引量:1
  • 5Jiu ling Wang,Ya qing Qie,Bing dong Zhu,Hong mei Zhang,Ying Xu,Qing zhong Wang,Jia zhen Chen,Wei Liu,Hong hai Wang.Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice[J]. Medical Microbiology and Immunology . 2009 (1) 被引量:1
  • 6Haley W. Sinn,Bennett D. Elzey,Robert J. Jensen,Xiuqin Zhao,Weicheng Zhao,Timothy L. Ratliff.The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity[J]. Cancer Immunology, Immunotherapy . 2008 (4) 被引量:1
  • 7Chen F,Liu C,Lindvall C.Epstein-Barr virus latent mem-brane 2A (LMP2A)down regulates telomerase reverse tran-scriptase (hTERT)in epithelial cell lines. International Journal of Cancer . 2005 被引量:1
  • 8Portis T,Longneeker R.Epstein-Barr virus LMP2A interfereswith global transcription factor regulation when expressed dur-ing B-lymphocyte development. Journal of Virology . 2003 被引量:1
  • 9Yao JZ.The research of rBCG effect of immunotherapy and an-ti-tumor activity. . 2002 被引量:1
  • 10Zhu W,,Xu AJ,Luo B.EB virus LMP2A,and BZLF1 fusiongene retroviral expression vector. Chin J Clin Rehabilit . 2007 被引量:1

二级参考文献10

  • 1KhannaR,BurrowsSR.RoleofcytotoxicTlymphocytesinEpsteinBarrvirus associateddisease[].AnnRevMicrobiol.2000 被引量:1
  • 2LiJH,ChiaM,ShiW ,etal.Tumor targetedgenetherapyfornasopharyngealcarcinoma[].Cancer Research.2002 被引量:1
  • 3MorseMA,LyerlyHK.DNAandRNAmodifieddendriticcellvaccines[].World Journal of Surgery.2002 被引量:1
  • 4SprinzlGM,KacaniL,SchrottFisherA ,etal.Dendriticcellvaccinesforcancertherapy[].Cancer Treatment Reviews.2001 被引量:1
  • 5BaumforthKRN,YoungLS,FlavellKJ ,etal.TheEpsteinBarrvirusanditsassociationwithhumancancers[].MolPathol.1999 被引量:1
  • 6KhannaR.ImmuneregulationinEpsteinBarrvirusassociateddiseases[].Microbiological Reviews.1995 被引量:1
  • 7StevenNM,AnnelsNE,KumarA ,etal.ImmediateearlyandearlylyticcycleproteinsarefrequenttargetsoftheEpsteinBarrvirus inducedcytotoxicTresponse[].The Journal of Experimental Medicine.1997 被引量:1
  • 8YaoK,PengGY,DingCL ,etal.AnalysisofthespecificcytotoxicTlymphocyteselicitedbydendriticCellstransfectedwiththeEBVlatentmembraneprotein2Arecombinantadenovirusinvitro[].ChinJImmunol. 被引量:1
  • 9WangRF,RosenbergR.Humantumorantigensforcancervaccinedevelopment[].Immunological Reviews.1999 被引量:1
  • 10KobieJJ,WuRS,KurtRA ,etal.Transforminggrowthfactorbetainhibitstheantigen presentingandanti tumoractivityofdendriticcellvaccines[].Cancer Research.1999 被引量:1

共引文献2

同被引文献16

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部